News Early Clovis approval notches up competition in ovarian canc... Clovis' Rubraca will compete against AstraZeneca rival.
News Clovis takes stock as rival Tesaro shines Oncology firm could make acquisition if ovarian cancer drug approved.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
